Dec 8 (Reuters) - Baudax Bio Inc:
* BAUDAX BIO INITIATES PHASE II CLINICAL TRIAL EVALUATING BX1000 IN PATIENTS UNDERGOING SURGERY
* BAUDAX BIO INC- RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL WILL STUDY BX1000 IN ABOUT 80 ADULT PATIENTS
* BAUDAX BIO-TO DATE, NO SERIOUS ADVERSE EVENTS HAVE BEEN REPORTED IN FIRST GROUP OF PATIENTS ENROLLED, EFFICACY PARAMETERS HAVE BEEN RECORDED IN TRIAL
* BAUDAX BIO INC- TO ANNOUNCING COMPLETION OF PRE-PLANNED FIRST INTERIM ANALYSIS OF BX1000 PHASE 2 SURGERY TRIAL EARLY IN 2023
* BAUDAX BIO INC- TARGET TO COMPLETE FULL STUDY ENROLLMENT BY END OF MARCH, 2023 Source text for Eikon: Further company coverage: